Transdermal iontophoretic drug delivery: mechanistic analysis and application to polypeptide delivery.
Three factors are of primary importance in determining the iontophoretic flux of a charged solute: the electrochemical potential gradient across the skin, an increase in skin permeability to passive transport due to iontophoresis (loosely defined as skin damage), and a current-induced water flux. The latter two factors can also affect the transport of uncharged solutes during iontophoresis. A method of correcting for the skin damage effect is introduced. The contributions of the water transport effect relative to that of the applied voltage drop for charged solutes is estimated. It is shown that the water transport contribution is generally lower than the contribution due to the applied voltage drop. The observed iontophonetic flux of the enhancement factors due to the applied voltage drop alone are compared with the theoretical predictions based on the constant field assumption. It is shown that the theoretical predictions are higher than the experimental observations. This work also examines, for the first time, a synergism of iontophoresis and pretreatment with a chemical penetration enhancer as a means for delivering high molecular weight polypeptides. It is shown that a 2-h pretreatment with absolute ethanol followed by iontophoresis dramatically increases the permeability coefficient of insulin through human skin.
Srinivasan
V
V
Department of Pharmaceutics, University of Utah, Salt Lake City 84112.
Higuchi
W I
WI
Sims
S M
SM
Ghanem
A H
AH
Behl
C R
CR
D000279:Administration, Cutaneous; D000818:Animals; D002021:Buffers; D002087:Butyrates / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D002951:Citrates / Q000494:pharmacology; D004566:Electrodes; D004573:Electrolytes / Q000032:analysis; D007328:Insulin / Q000008:administration & dosage; D007478:Iontophoresis; D008567:Membranes, Artificial; D051379:Mice; D008812:Mice, Hairless; D010455:Peptides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D012869:Skin Absorption / Q000187:drug effects; D013757:Tetraethylammonium Compounds / Q000378:metabolism
D002021:Buffers; D002087:Butyrates; D002951:Citrates; D004573:Electrolytes; D007328:Insulin; D008567:Membranes, Artificial; D010455:Peptides; D004364:Pharmaceutical Preparations; D013757:Tetraethylammonium Compounds